Literature DB >> 25224342

Pre-formulation studies of resveratrol.

Keila Robinson1, Charlotta Mock, Dong Liang.   

Abstract

CONTEXT: Resveratrol, a natural compound found in grapes, has potential chemotherapy effects but very low oral bioavailability in humans.
OBJECTIVE: To evaluate the solubility, pH stability profile, plasma protein binding (PPB) and stability in plasma for resveratrol.
METHODS: Solubility of resveratrol was measured in 10 common solvents at 25 °C using HPLC. The solution state pH stability of resveratrol was assessed in various United States Pharmacopeia buffers ranging from pH 2 to 10 for 24 h at 37 °C. Samples were analyzed up to 24 h. Human PPB was determined using ultracentrifugation technique. Standard solutions of drug were spiked to blank human plasma to yield final concentrations of 5, 12.5 or 25 μg/mL for determination. Finally, stability of resveratrol in human and rat plasma was also assessed at 37 °C. Aliquots of blank plasma were spiked with a standard drug concentration to yield final plasma concentration of 50 μg/mL. Samples were analyzed for resveratrol concentration up to 96 h.
RESULTS: Resveratrol has wide solubility ranging from 0.05 mg/mL in water to 374 mg/mL in polyethylene glycol 400 (PEG-400). Resveratrol is relatively stable above pH 6 and has maximum degradation at pH 9. The mean PPB of resveratrol is 98.3%. Resveratrol degrades in human and rat plasma in a first-order process with mean half lives of 54 and 25 h, respectively.
CONCLUSION: Resveratrol is more soluble in alcohol and PEG-400 and stable in acidic pH. It binds highly to plasma proteins and degrades slower in human then rat plasma.

Entities:  

Keywords:  Natural compound; physiochemical evaluation; plasma protein binding; polyphenol; solubility; stability

Mesh:

Substances:

Year:  2015        PMID: 25224342      PMCID: PMC4427559          DOI: 10.3109/03639045.2014.958753

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  13 in total

Review 1.  Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum.

Authors:  Andreas J Gescher; William P Steward
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

2.  Aggregation state and pKa values of (E)-resveratrol as determined by fluorescence spectroscopy and UV-visible absorption.

Authors:  José Manuel López-Nicolás; Francisco García-Carmona
Journal:  J Agric Food Chem       Date:  2008-08-14       Impact factor: 5.279

3.  High-performance liquid chromatography spectrometric analysis of trans-resveratrol in rat plasma.

Authors:  Hui He; Xijing Chen; Guangji Wang; Jiping Wang; Andrew Keith Davey
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-01-30       Impact factor: 3.205

Review 4.  Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer.

Authors:  Dominique Delmas; Allan Lançon; Didier Colin; Brigitte Jannin; Norbert Latruffe
Journal:  Curr Drug Targets       Date:  2006-04       Impact factor: 3.465

5.  Determination of trans-resveratrol in plasma by HPLC.

Authors:  M E Juan; R M Lamuela-Raventós; M C de la Torre-Boronat; J M Planas
Journal:  Anal Chem       Date:  1999-02-01       Impact factor: 6.986

6.  High absorption but very low bioavailability of oral resveratrol in humans.

Authors:  Thomas Walle; Faye Hsieh; Mark H DeLegge; John E Oatis; U Kristina Walle
Journal:  Drug Metab Dispos       Date:  2004-08-27       Impact factor: 3.922

7.  Preformulation stability of trans-resveratrol and trans-resveratrol glucoside (Piceid).

Authors:  James S Jensen; Christian F Wertz; Victoria A O'Neill
Journal:  J Agric Food Chem       Date:  2010-02-10       Impact factor: 5.279

8.  Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.

Authors:  Yi-Ping Qian; Yu-Jun Cai; Gui-Juan Fan; Qing-Yi Wei; Jie Yang; Li-Fang Zheng; Xiu-Zhuang Li; Jian-Guo Fang; Bo Zhou
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

9.  The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol.

Authors:  Surajit Das; Hai-Shu Lin; Paul C Ho; Ka-Yun Ng
Journal:  Pharm Res       Date:  2008-07-16       Impact factor: 4.200

10.  Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.

Authors:  David J Boocock; Guy E S Faust; Ketan R Patel; Anna M Schinas; Victoria A Brown; Murray P Ducharme; Tristan D Booth; James A Crowell; Marjorie Perloff; Andreas J Gescher; William P Steward; Dean E Brenner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  19 in total

1.  Resveratrol Delivery from Porous Poly(lactide- co-glycolide) Scaffolds Promotes an Anti-Inflammatory Environment within Visceral Adipose Tissue.

Authors:  Kendall P Murphy; Michael A Hendley; Christopher Isely; Prakasam Annamalai; Edsel Peña; R Michael Gower
Journal:  ACS Appl Mater Interfaces       Date:  2018-12-07       Impact factor: 9.229

Review 2.  Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence.

Authors:  Ana Cláudia Santos; Irina Pereira; Mariana Magalhães; Miguel Pereira-Silva; Mariana Caldas; Laura Ferreira; Ana Figueiras; António J Ribeiro; Francisco Veiga
Journal:  AAPS J       Date:  2019-04-23       Impact factor: 4.009

3.  Fully Natural Lecithin Encapsulated Nano-Resveratrol for Anti-Cancer Therapy.

Authors:  Meiyi Liang; Mingyan Guo; Phei Er Saw; Yandan Yao
Journal:  Int J Nanomedicine       Date:  2022-05-06

4.  Resveratrol as a Promising Polyphenol in Age-Associated Cardiac Alterations.

Authors:  Denise Börzsei; Judith Sebestyén; Renáta Szabó; Zelma Nadin Lesi; Andrea Pálszabó; Patrícia Pálszabó; András Szász; Dániel Priksz; Béla Juhász; Médea Veszelka; Zsolt Turcsán; Zoltán Deim; Csaba Varga; Anikó Pósa
Journal:  Oxid Med Cell Longev       Date:  2022-06-18       Impact factor: 7.310

5.  Anti-insulin resistance effect of constituents from Senna siamea on zebrafish model, its molecular docking, and structure-activity relationships.

Authors:  Wanlapa Nuankaew; Armad Heemman; Chatchai Wattanapiromsakul; Ji Heon Shim; Na Woo Kim; Tamanna Yasmin; Seo Yule Jeong; Youn Hee Nam; Bin Na Hong; Sukanya Dej-Adisai; Tong Ho Kang
Journal:  J Nat Med       Date:  2021-02-23       Impact factor: 2.343

6.  Fusogenic liposomes effectively deliver resveratrol to the cerebral microcirculation and improve endothelium-dependent neurovascular coupling responses in aged mice.

Authors:  Tabea Wiedenhoeft; Stefano Tarantini; Ádám Nyúl-Tóth; Andriy Yabluchanskiy; Tamas Csipo; Priya Balasubramanian; Agnes Lipecz; Tamas Kiss; Anna Csiszar; Agnes Csiszar; Zoltan Ungvari
Journal:  Geroscience       Date:  2019-10-25       Impact factor: 7.713

Review 7.  Resveratrol-loaded nanomedicines for cancer applications.

Authors:  Manjusha Annaji; Ishwor Poudel; Sai H S Boddu; Robert D Arnold; Amit K Tiwari; R Jayachandra Babu
Journal:  Cancer Rep (Hoboken)       Date:  2021-03-02

8.  Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model.

Authors:  Mingyu Lee; Chun Gwon Park; Beom Kang Huh; Se-Na Kim; Seung Ho Lee; Roza Khalmuratova; Jong-Wan Park; Hyun-Woo Shin; Young Bin Choy
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

9.  Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy.

Authors:  Shivaprasad Gadag; Reema Narayan; Archana S Nayak; Diana Catalina Ardila; Shilpa Sant; Yogendra Nayak; Sanjay Garg; Usha Y Nayak
Journal:  Int J Pharm       Date:  2021-07-10       Impact factor: 6.510

10.  Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model.

Authors:  Adam Riba; Laszlo Deres; Balazs Sumegi; Kalman Toth; Eszter Szabados; Robert Halmosi
Journal:  Oxid Med Cell Longev       Date:  2017-10-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.